Impaired NK cell recognition of vemurafenib-treated melanoma cells is overcome by simultaneous application of histone deacetylase inhibitors

Impaired NK cell recognition of vemurafenib-treated melanoma cells is overcome by simultaneous application of histone deacetylase inhibitors

Therapy of metastatic melanoma advanced recently with the clinical implementation of signalling pathway inhibitors, such as vemurafenib, specifically targeting mutant BRAFV600E. In general, patients experience remarkable clinical responses under BRAF inhibitor (BRAFi) treatment but eventually progre...

Full description

Bibliographic Details
Main Authors: Sheila López-Cobo, Natalia Pieper, Carmen Campos-Silva, Eva M. García-Cuesta, Hugh T. Reyburn, Annette Paschen, Mar Valés-Gómez
Format: Article
Language:English
Published: Taylor & Francis Group 2018-02-01
Series:OncoImmunology
Subjects:
nk cell
nkg2d
braf inhibitors
melanoma
combination therapy
hdac inhibitor
dnam1
Online Access:http://dx.doi.org/10.1080/2162402X.2017.1392426

Internet

http://dx.doi.org/10.1080/2162402X.2017.1392426

Similar Items